12/20
06:00 am
eols
Is Evolus, Inc. approaching profitability? [Yahoo! Finance]
Medium
Report
Is Evolus, Inc. approaching profitability? [Yahoo! Finance]
12/13
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/22
08:11 am
eols
COSMETIC EXECUTIVE WOMEN (CEW) HONORS THE BEST IN BEAUTY [Yahoo! Finance]
Medium
Report
COSMETIC EXECUTIVE WOMEN (CEW) HONORS THE BEST IN BEAUTY [Yahoo! Finance]
11/18
02:20 pm
eols
Botox Competitor Jeuveau Launches A $49-A-Month Membership [Forbes]
Low
Report
Botox Competitor Jeuveau Launches A $49-A-Month Membership [Forbes]
11/18
11:38 am
eols
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Low
Report
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
11/14
11:31 am
eols
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) [Yahoo! Finance]
Low
Report
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) [Yahoo! Finance]
11/9
09:50 am
eols
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]
Low
Report
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]
11/7
08:36 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
High
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
11/7
06:17 am
eols
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges [Yahoo! Finance]
High
Report
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges [Yahoo! Finance]
11/6
08:28 pm
eols
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
High
Report
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/6
04:05 pm
eols
Evolus Reports Third Quarter 2024 Results
High
Report
Evolus Reports Third Quarter 2024 Results
11/1
08:15 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
11/1
08:00 am
eols
Evolus to Participate in Stifel 2024 Healthcare Conference
Low
Report
Evolus to Participate in Stifel 2024 Healthcare Conference
10/31
02:07 pm
eols
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation [Yahoo! Finance]
Low
Report
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation [Yahoo! Finance]
10/31
02:02 pm
eols
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
Low
Report
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
10/29
08:00 am
eols
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
Medium
Report
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
10/23
08:00 am
eols
Evolus to Report Third Quarter Financial Results on November 6, 2024
Medium
Report
Evolus to Report Third Quarter Financial Results on November 6, 2024
10/11
10:53 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10
12:03 pm
eols
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years [Yahoo! Finance]
Low
Report
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years [Yahoo! Finance]
10/3
08:18 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
9/27
09:00 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)